Robert Buckley Sells 1,423 Shares of Novanta (NASDAQ:NOVT) Stock

Novanta Inc. (NASDAQ:NOVT) CFO Robert Buckley sold 1,423 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $140.88, for a total value of $200,472.24. Following the sale, the chief financial officer directly owned 93,814 shares in the company, valued at approximately $13,216,516.32. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Robert Buckley also recently made the following trade(s):

• On Wednesday, January 21st, Robert Buckley sold 1,423 shares of Novanta stock. The stock was sold at an average price of $140.14, for a total value of $199,419.22.

Novanta Trading Down 3.1%

NOVT opened at $133.22 on Thursday. The company has a 50-day simple moving average of $132.74 and a 200 day simple moving average of $120.13. The stock has a market capitalization of $4.75 billion, a price-to-earnings ratio of 91.25 and a beta of 1.62. The company has a quick ratio of 1.54, a current ratio of 3.69 and a debt-to-equity ratio of 0.16. Novanta Inc. has a twelve month low of $98.27 and a twelve month high of $153.20.

Novanta (NASDAQ:NOVT) last issued its earnings results on Monday, February 23rd. The technology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novanta had a return on equity of 13.12% and a net margin of 5.49%.The firm had revenue of $258.35 million for the quarter, compared to the consensus estimate of $260.72 million. During the same quarter last year, the business posted $0.76 EPS. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. Analysts predict that Novanta Inc. will post 3.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Robert W. Baird set a $150.00 target price on shares of Novanta in a report on Wednesday. Zacks Research raised shares of Novanta from a “strong sell” rating to a “hold” rating in a research note on Friday, January 16th. Finally, Weiss Ratings upgraded shares of Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 20th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $150.00.

Hedge Funds Weigh In On Novanta

Several hedge funds and other institutional investors have recently bought and sold shares of NOVT. Invesco Ltd. grew its holdings in Novanta by 9.0% during the 4th quarter. Invesco Ltd. now owns 68,089 shares of the technology company’s stock worth $8,102,000 after acquiring an additional 5,600 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Novanta in the 4th quarter valued at about $275,000. Alberta Investment Management Corp bought a new stake in shares of Novanta during the 4th quarter valued at about $1,285,000. Mercer Global Advisors Inc. ADV acquired a new stake in Novanta during the fourth quarter worth approximately $314,000. Finally, Empowered Funds LLC grew its stake in Novanta by 16.7% during the fourth quarter. Empowered Funds LLC now owns 7,888 shares of the technology company’s stock worth $939,000 after purchasing an additional 1,128 shares during the period. Institutional investors and hedge funds own 98.35% of the company’s stock.

Novanta Company Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.